FDA approves rilzabrutinib tablets as a new oral treatment option for adults with persistent or chronic ITP who show insufficient response to standard therapies...
The FDA has authorized omalizumab-igec as the first interchangeable biosimilar to omalizumab for treating asthma, urticaria, chronic rhinosinusitis with nasal p...
The FDA has proposed requisition of front-of-package nutrition labels on most packaged foods to clearly display levels of saturated fat, sodium, and added sugar...
EMA recommends updated trivalent influenza vaccines for the 2025/2026 season, selecting strains based on global surveillance data and excluding B/Yamagata due t...
Dr. Reddy’s has secured exclusive U.S. and Europe commercialization rights for Henlius’s daratumumab biosimilar HLX15 in a deal worth up to $131.6 m...
Dr. Reddy’s and Bio-Thera Solutions have entered into exclusive commercialization and license agreements for two proposed biosimilars—BAT2206 (ustek...
Fitusiran, a groundbreaking treatment for hemophilia A and B is approved by the FDA, offering a less frequent dosing schedule of once every 2 months. This appro...
Dupilumab has received FDA approval for chronic spontaneous urticaria in patients aged 12 years and older, expanding its use to over 300,000 U.S. patients follo...
Suzetrigine is a crucial non-opioid alternative for managing acute pain, helping to reduce reliance on opioids while ensuring effective patient relief.
